Sun Pharma Inks Global Licensing Deal With LIB Therapeutics For PCSK9 Inhibitor
Mumbai: Sun Pharmaceutical Industries Limited on Monday announced a global licensing and commercialisation agreement with LIB Therapeutics Inc. for lerodalcibep, a PCSK9 inhibitor used to lower LDL-C. EU Approval and Market Lerodalcibep, branded Lyrokaul, received EU approval on 21 September 2026 for treating adult patients with hypercholesterolaemia and mixed dyslipidaemia. The company said this…
We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.
